Long‐term follow‐up of web‐based and group‐based behavioural intervention in NAFLD in a real world clinical setting
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17768 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Maria Letizia Petroni and 7 co-authors. Institution: IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease. Cited 13 times so far (Crossref); 56 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Fatty Liver-Inhibition to Progression.
Abstract (original language)
Background
The long‐term results of web‐based behavioural intervention in non‐alcoholic fatty liver disease (NAFLD) have not been described in patients followed in specialised centres.
Aims
To analyse the long‐term effectiveness of web education compared with the results achieved by a group‐based behavioural intervention in the same years 2012–2014.
Methods
We followed 679 patients with NAFLD (web‐based, n = 290; group‐based, n = 389) for 5 years. Weight loss ≥10% was the primary outcome; secondary outcomes were attrition, changes in liver enzymes and in biomarkers of steatosis (Fatty liver Index) and fibrosis (Fibrosis‐4 index).
Results
The cohorts differed in age, education, working status and presence of diabetes. Attrition was higher in the web‐based cohort (hazard ratio: 1.53; 95% CI: 1.24–1.88), but not different after adjustment for confounders. Among patients in active follow‐up, 50% lost ≥5% of initial body weight and 19% lost ≥10%, without difference between cohorts. Alanine aminotransferase levels fell to within the normal range in 51% and 45% of web‐ and group‐based cohorts, respectively. Fatty Liver Index declined progressively and, by year 5, it ruled out steatosis in 4.8%, whereas 24.9% were in the indeterminate range. Fibrosis‐4 index increased in both cohorts, driven by age, but the prevalence of cases ruling‐in advanced fibrosis remained very low (around 1%). Improvements in the class of both surrogate biomarkers were associated with ≥5% weight loss.
Conclusions
Although burdened by attrition, web‐based behavioural intervention is feasible and effective in NAFLD, expanding the cohort involved in behavioural programs and reducing the risk of progressive disease.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- IRCCS-Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical Sciences, Division of Gastroenterology and Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
- Department of Mathematical, Physical and Computer Sciences, University of Parma, Parma, Italy.
- Department of Computer Science and Engineering, Alma Mater University of Bologna, Bologna, Italy.
ORCID profiles: Maria Letizia Petroni, Santo Colosimo, Lucia Brodosi, Angelo Armandi, Flavio Bertini, Danilo Montesi, Elisabetta Bugianesi, Giulio Marchesini
Funding
- Fatty Liver-Inhibition to Progression
Cite
APA
Petroni, M. L., Colosimo, S., Brodosi, L., Armandi, A., Bertini, F., Montesi, D., Bugianesi, E., & Marchesini, G. (2024). Long‐term follow‐up of web‐based and group‐based behavioural intervention in NAFLD in a real world clinical setting. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17768
Vancouver
Petroni ML, Colosimo S, Brodosi L, Armandi A, Bertini F, Montesi D, et al. Long‐term follow‐up of web‐based and group‐based behavioural intervention in NAFLD in a real world clinical setting. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17768
BibTeX
@article{Petroni2024,
author = {Petroni, Maria Letizia and Colosimo, Santo and Brodosi, Lucia and Armandi, Angelo and Bertini, Flavio and Montesi, Danilo and Bugianesi, Elisabetta and Marchesini, Giulio},
title = {Long‐term follow‐up of web‐based and group‐based behavioural intervention in NAFLD in a real world clinical setting},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17768}
}
EUVIMED